Method for the treatment of demyelinating diseases

 

(57) Abstract:

The invention relates to medicine, in particular, neurology, and can be used for the treatment of immune disorders in patients with demyelinating diseases (multiple sclerosis, multiple encephalomyelitis). The method involves the administration of drugs thymus or their synthetic analogues and glucocorticoids. Drugs administered in therapeutically acceptable doses paired injections parafusulina lymphotropic in miastenia the intervals of the hands and/or milusheva periods stop in the center of the intervals in the direction toward the rear at a depth of 0.5 to 2.0 cm, in the amount of from 5.0 to 15.0 ml as the basis for a solution using lymphotropic the drug. The first course is injected drug the thymus gland or its synthetic analogue, and glucocorticoid together in the form of a solution in the ratio of no less than 10 pairs of injections a day. Then carry out a joint drug thymus or its synthetic analogue and interferon inducer and/or peptide of immunostimulant in the form of a solution in the ratio of 5 paired injections a day. Then repeat the introduction of drugs in the first course with the interval between injections in 5-7 days for 4 weeks is Ranov and systems of the body and from the side effects of drugs traditionally used for this pathology.

The method of treatment relates to the field of medicine, in particular, neurology, and can be used for the treatment of immune disorders in patients with demyelinating diseases of the nervous system (multiple sclerosis, multiple encephalomyelitis).

Patients demyelination diseases of the nervous system represent one of the most difficult problems of neurology in the treatment plan, because finally the cause of the disease up to the present time nevyjasnennyh. The leading theory in the etiology of this group of diseases is the autoimmune theory, according to which the immediate cause of this disease is a long-term persistent viral infection that causes disturbances in the immune system at the level of formation of the functional orientation of immune cells leading to autoimmune attack with damage to the myelin. This group of diseases, in particular multiple sclerosis is an incurable disease. Influencing the infectious agent has not led to success, equally as vaccination (Diseases of the nervous system, manual Ed. by N. N. Yakhno, D. R. Of Stulman, P. C. Melnychuk, Moscow, 1997).

Closest to the claimed and selected as a prototype is a method of administering drugs, in particular drugs thymus and glucocorticoids in the blood stream, multiple sclerosis and other diseases involving damage myelin. In this method, the adjuvant and dexamethasone administered intramuscularly in doses: thymalin 10 mg and dexamethasone 4 mg daily, respectively, for 10 days. The disadvantage of this method is the low effect of treatment is able to achieve the stabilization process for a short period of time, as well as the presence of side reactions of an organism in response to prolonged use of glucocorticoids (Diseases of the nervous system, manual Ed. by N. N. Yakhno, D. R. Of Stulman, P. C. Melnychuk, Moscow, 1997).

The objective of the invention is to develop an effective method for the treatment of patients with demyelination diseases, operable on the stage of differentiation and formation options is Kimi results which can be achieved using the proposed method are:

- improving the efficiency of treatment of patients with demyelination diseases;

- ensuring the possibility of penetration of drugs in the zone of formation of the functional activity of immunocompetent cells;

- save the pharmacological activity of drugs in the transport process in the area of therapeutic action;

- prevention of disability of patients and maintaining their ability to work.

Problem solving and the achievement of the above results became possible due to the fact that in the known method for the treatment of demyelinating diseases, including the introduction of preparations of thymus or their synthetic analogues and glucocorticoids, drugs administered in therapeutically acceptable doses, parafusulina lymphotropic pair, and/or miastenia periods of both brushes, and/or milusheva intervals of both feet, or mirasty period of brushes and Besplatniy the span of the foot in the center of the intervals in the direction toward the rear at a depth of 0.5 to 2.0 cm, in the amount of from 5.0 to 15.0 ml, as the basis of the solution using lymphotropic drug the first course enter product is its 10 paired injections a day, then carry out a joint drug thymus or its synthetic analogue and interferon inducer and/or peptide of immunostimulant in the form of a solution in the ratio of 5 paired injections a day, then repeat the introduction of drugs in the first course with the interval between injections in 5-7 days for 4 weeks.

The introduction of the inventive combination of drugs in the organism by known methods, i.e., directly into the blood stream, does not provide a satisfactory effect in the treatment of demyelinating diseases. Only connect to the specified set of features of the operation of the introduction of these drugs in the region, with well-vascularized lymph capillaries, when the claimed conditions and mode of administration allows to achieve significant positive results in the treatment of demyelinating diseases. This can be explained, on the one hand, the fact that the blood flow drugs thymus, peptide immunostimulant, interferon inducers (cycloferon and its analogs) are metabolized and act in a modified form in the peripheral organs of immunogenesis, and on the other hand, the fact that injected into the bloodstream drugs act on cells of the immune these cells at the time of differentiation and formation of the functional activity of the latter in the organs of immunogenesis. Given that "defect" by immunocompetent cells occurs in the process of their differentiation and formation of functional activity in peripheral organs of immunogenesis (lymphatic system), delivery of drugs directly into these bodies can prevent the occurrence of this "defect", as the flow of lymph is carried out from the periphery to the center of the thoracic lymphatic duct, that is, put the drugs come in the process of the current in the regional lymph nodes and may exert their regulatory effect on immunocompetent cells during the formation of their functional activity.

The invention is not obvious from the prior art. The prior art is not identified technical solution of the same purpose, a set of features identical essential features of the claimed invention.

The method is as follows: prepare a mixture of the drug thymus or its synthetic analogue and glucocorticoid in solution lymphotropic substances in the claimed amount (from 5.0 to 15.0 ml), subject to valid pharmacological doses. As lymphotropic preparation (solvent) use of prep is the super lymphotropic pair enter and/or miastenia periods of both hands, and/or milusheva intervals of both feet, or mirasty period of brushes and Besplatniy the span of the foot with one hand on the center of the intervals by injection with a syringe in the direction toward the rear at a depth of 0.5 to 2.0 cm, in the amount of from 5.0 to 15.0 ml During the first year of the injected drug the thymus gland or its synthetic analogue, and glucocorticoid together in the form of a solution in the ratio of no less than 10 pairs of injections a day. At this location the introduction, their rotation is determined based on the pattern of the disease. In severe cases, possibly fresh introduction to the stated periods of both hands and both feet at the same time.

Then enter together drug thymus or its synthetic analogues and interferon inducer and/or peptide immunostimulant in the form of a solution in the ratio of five paired injections a day. After that, repeat the introduction of drugs in the first course, the interval between injections establish 5-7 days for 4 weeks.

The practical applicability of the method is illustrated by the following examples of specific performance.

Example 1. Patient O., 34 years suffers from multiple sclerosis, spinal form, with elements of Tetra is in the acute phase of the disease.

On the background of basic therapy were treated intramuscularly was introduced:

The preparation of thymus - Taktivin

The product of the number of glucocorticoid - Prednisolone

Lymphotropic drug - Novocaine

Injected volume, ml - 5

The number of introductions - 10

The interval between doses, days Daily

that is not consistent with the stated method of administration.

Observed stabilization of the pathological process. However, regression of focal pathology was not observed.

Example 2. This same patient one month was admitted to the Department of neurology 1 city hospital with the same diagnosis in the acute phase (increased phenomenon of tetraparesis, the phenomenon of incontinence remained, appeared unstable gait). On the background of basic therapy, the patient made parabasal lymphotropic by the present method:

The preparation of thymus - Thymalin

The product of the number of glucocorticoid is Dexamethasone

Lymphotropic drug - Novocaine

Depth of insertion, cm - 0,5

Injected volume, ml - 5

The number of paired introductions (alternating pairs introduction miastenia intervals brushes and milusheva periods stop) - 10

The interval between the introduction days - LASS="ptx2">

After 3 injections were observed regression of hyperreflexia, after 5 injections - regression of pathological signs, after 10 injections - regression nystagmus, ataxic disorders and normal urination. Then the patient without the basic therapy conducted parabasal lymphotropic by the present method:

The preparation of thymus - Thymalin

The preparation of a number of peptides Immunostimulants - Imunofan

Lymphotropic drug - Novocaine

Depth of insertion, cm - 1,0

Injected volume, ml - 5

The number of paired introductions - 5

The interval between doses, days - 1

Further patient without basic therapy conducted parabasal lymphotropic by the present method:

The preparation of thymus - Thymalin

The product of the number of glucocorticoid is Dexamethasone

Lymphotropic drug - Novocaine

Depth of insertion, cm - 1,0

Injected volume, ml - 5

The number of paired introductions (alternating pairs of injections in Milosevic period of brushes and mirasty the span of the foot from the right or left side of the body) - 5

The interval between doses, days 5 - 7

The patient is observed for 3 months, feels healthy, clinical signs of disease is, the urination on the type of incontinence.

On the background of basic therapy were treated intramuscularly was introduced:

The preparation of thymus - Thymalin

The product of the number of glucocorticoid is Dexamethasone

The preparation of a number of inductors of interferon - Cycloferon

The number of introductions - 5

The interval between doses, days - 1

There has been little positive dynamics in terms of recourse lower paraparesis at one point.

Example 4. The same patient after two months, was admitted to the neurology Department 1 city hospital with the same diagnosis in the acute phase. The lower prepares reached up to one or two points.

Without basic therapy were treated by the claimed method was introduced:

The preparation of thymus - Thymalin

The product of the number of glucocorticoid is Dexamethasone

The preparation of a number of inductors of interferon - Cycloferon

Lymphotropic drug - Novocaine

Depth of insertion, cm - 2,0

Injected volume, ml - 10,0

The number of injections (twice the drugs were injected two pairs simultaneously in milusheva intervals brushes and miastenia intervals foot) - 15

The interval between doses, days - 1

Example 5. Patient B. , 25 years, suffering from multiple encephalomyelitis, lower prepares, urination on the type of incontinence. He enrolled in the acute phase.

On the background of basic therapy were treated intramuscularly was introduced:

The preparation of thymus - Taktivin

The product of the number of glucocorticoid - Prednisolone

Lymphotropic drug - Novocaine

Injected volume, ml - 8,0

The number of introductions - 10

The interval between doses, days Daily

that is not consistent with the stated method of administration.

Observed stabilization of the pathological process. However, regression of focal pathology was not observed.

Example 6. This same patient one month was admitted to the Department of neurology 1 city hospital with the same diagnosis. On the background of basic therapy, the patient made parabasal lymphotropic by the present method:

The preparation of thymus - Thymalin

The product of the number of glucocorticoid is Dexamethasone

Lymphotropic drug - Novocaine

Depth of insertion, cm - 1,5

Injected volume, ml - 10,0

The number of paired introductions - 10

(alternating injections in miastenia periods of both hands and in magplus the WMD limit on the depth of injection and the volume of injected mixture.

After 4 injections were observed regression of hyperreflexia, after 6 injections - regression of pathological signs, after 10 injections - regression ataxic disorders and normal urination. Then the patient without the basic therapy conducted parabasal lymphotropic by the present method:

The preparation of thymus - Thymalin

The preparation of a number of peptides Immunostimulants - Imunofan

Lymphotropic drug - Novocaine

Depth of insertion, cm - 0,5

Injected volume, ml - 5

The number of paired introductions - 5

(alternating injections in miastenia periods of both hands and in milusheva intervals of both feet)

The interval between doses, days - 1

Further patient without basic therapy conducted parabasal lymphotropic by the present method:

The preparation of thymus - Thymalin

The product of the number of glucocorticoid is Dexamethasone

Lymphotropic drug - Novocaine

Depth of insertion, cm - 1,0

Injected volume, ml - 5

The number of paired introductions (only in miastenia intervals brushes) - 5

The interval between doses, days 5 - 7

which corresponds to the maximum value of the input substances.

Bol Patient A., 30 years, with a diagnosis of Disseminated encephalomyelitis, lower prepares, urination on the type of incontinence, ataxic syndrome. The disease duration of 5 years.

On the background of basic therapy were treated intramuscularly was introduced:

The preparation of thymus - Thymalin

The product of the number of glucocorticoid is Dexamethasone

The preparation of a number of inductors of interferon - Cycloferon

The number of introductions - 5

The interval between doses, days - 1

There has been little positive dynamics in terms of recourse lower paraparesis at one point.

Example 8. The same patient after two months, was admitted to the neurology Department 1 city hospital with the same diagnosis. The lower prepares reached two scores.

Without basic therapy were treated by the claimed method was introduced:

The preparation of thymus - Thymalin

The product of the number of glucocorticoid is Dexamethasone

The preparation of a number of inductors of interferon - Cycloferon

Lymphotropic drug Lidocaine

Depth of insertion, cm - 0,5

Injected volume, ml - 5

The number of introductions - 15

The interval between doses, days - 1

There was a significant pological.

In all cases, the use of the claimed method are positive clinical results. If you deviate from the proposed limits of the place of introduction, the depth of injection and the volume of the injected mixture, the claimed composition, the multiplicity of the introduction - positive results are missing or they are not pronounced. Only connect to the specified set of features of the operation of the introduction of these drugs in the region, with well-vascularized lymph capillaries under the present conditions, the composition and mode of administration allows to achieve the expected results.

Treatment is carried out until 22 injections offered drugs by this method with breaks between the introduction 1-7 days. The first effect, which is manifested in the reduction of musculoskeletal disorders observed after 3 injections. After 5-10 injection in all patients there has been regression manifestations of cerebellar pathology. And at the end of treatment normalized the function of urination. In the future, patients were observed by us for 5 months all the patients showed a stable remission.

As can be seen from the examples, due to the inventive combination of significant differences to implement principiorum joint injection from a number of preparations of thymus or their synthetic analogues and interferon inductors (cold) and/or peptide of Immunostimulants (immunofan), in the form of a solution based on lymphotropic or infostealers solvent and glucorticoids patients with demyelination diseases are easy to use, can significantly improve the efficiency of treatment of patients suffering from demyelination diseases, to reduce the duration of treatment of patients, to reduce the cost of treatment of patients with demyelination diseases, to prevent complications of other organs and body systems in patients with this pathology, arising under the influence of the disease and side effects of the drugs used in the treatment of these patients according to traditional methods. The inventive method is based on a fundamentally new approach to the treatment of demyelinating diseases.

Method for the treatment of demyelinating diseases, including the introduction of preparations of thymus or their synthetic analogues and glucocorticoids, characterized in that the drugs are administered in therapeutically acceptable doses paired injections parafusulina lymphotropic in miastenia the intervals of the hands and/or milusheva periods stop in the center of the intervals in the direction toward the rear at a depth of 0.5 to 2.0 cm, in the amount of from 5.0 to 15.0 ml, as the basis eticheski similar and glucocorticoid together in the form of a solution in the ratio of no less than 10 pairs of injections a day, then carry out a joint drug thymus or its synthetic analogue and interferon inducer and/or peptide of immunostimulant in the form of a solution in the ratio of 5 paired injections a day, then repeat the introduction of drugs in the first course, with the interval between injections in 5-7 days for 4 weeks.

 

Same patents:

The invention relates to medicine and relates to methods and compositions to enhance immune responses, mediated protein made of antibodies and cytokines, through co-injection of prostaglandin inhibitor

The invention relates to medicine, namely to gynecology and venereology, and can be used for the treatment of urogenital chlamydia trachomatis in women
The invention relates to medicine and relates to tools having immunomodulatory, antiviral, antibacterial, regenerative, reparative, membrane - and hepatoprotective action
The invention relates to medicine, namely to the chemical-pharmaceutical industry

The invention relates to medicine, namely to pharmaceutical compositions intended for the prevention and treatment of stress and developing on the background of viral diseases and diseases associated with decreased immunity

The invention relates to medicine, namely to the development of new dosage forms of the biologically active peptide compounds

The invention relates to medicine

The invention relates to medicine and concerns immunostimulant, calling specific to the tumor cell immune response, and method of its production

The invention relates to medicine and relates to a preventive or therapeutic agent for treatment of inflammatory bowel diseases like Crohn's disease or ulcerative colitis, and that the agent comprises as an active ingredient such antagonist of interleukin-6 (IL-6), as the antibody against the receptor of IL-6

The invention relates to peptides having the amino acid sequence of at least 5 amino acids are identical to part ner receptor, corresponding to amino acids 308-373 this receptor, excluding the peptide TEKKRRETVEREKE

The invention relates to medicine and biology, more specifically a process for the production of collagen, and can be used in the treatment of various tissue pathologies, for cell cultivation

The invention relates to medicine, in particular to immunology, and for inhibition of lymphocyte proliferation

The invention relates to the field of medicine and biotechnology and concerns peptide antagonists Sonoline

The invention relates to venereology and, in particular, to the treatment of syphilis in the absence of positive to negative reactions Wasserman

The invention relates to medicine and for the treatment and prevention of cholelithiasis

The invention relates to medicine and relates to the use of proteins as antiretrovirals

The invention relates to peptides consisting of 16-55 amino acid residues, the peptides comprise at least one of the amino acid sequence: FLCTHIIYS (SEQ ID NO:61), IIYSFANIS (SEQ ID NO: 62), FIKSVPPFL (SEQ ID NO:64), FDGLDLAWL (SEQ ID NO:65), LYPGRRDKQ (SEQ ID NO: 66), YDIAKISQH (SEQ ID NO:67), LDFISIMTY (SEQ ID NO:68), FISIMTYDF (SEQ ID NO: 69), FRGQEDASP (SEQ ID NO: 70), YAVGYMLRL (SEG ID NO:71), MLRLGAPAS (SEQ ID NO:72), LAYYEICDF (SEQ ID NO:73), LRGATVHRT (SEQ ID NO: 74), YLKDRQLAG (SEQ ID NO:75), LAGAMVWAL (SEQ ID NO:76), VWALDLDDF (SEQ ID NO: 77) or LDLDDFQGS (SEQ ID NO:78)

The invention relates to medicine, in particular to immunology and endocrinology, and can be used for the treatment and prevention of immunodeficiency diseases and conditions caused by lack of iodine in the body
Up!